Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases.
Morphic Therapeutic has raised $276.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2023.
Morphic Therapeutic's investors include AbbVie, Polaris Partners, Invus, Novo Holdings, SR One.
Morphic Therapeutic is headquartered in Waltham, United States.
Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases.
Morphic Therapeutic is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Morphic Therapeutic — Funding & Investors." VCBacked, May 3, 2023, https://www.vcbacked.co/company/morphic-therapeutic. Accessed August 7, 2026.
VCBacked. (2023). Morphic Therapeutic — Funding & Investors. Retrieved August 7, 2026, from https://www.vcbacked.co/company/morphic-therapeutic
{{cite web |title=Morphic Therapeutic — Funding & Investors |url=https://www.vcbacked.co/company/morphic-therapeutic |website=VCBacked |access-date=August 7, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated